increase the carcinogenicity of tobacco use; (3) asbestos exposure; (4) obesity and/or a high-fat diet; (5) long-term exposure to dialysis; and (6) advancing age and/or male gender. 3 Approximately one third of patients will have metastatic disease at presentation, and 40% of individuals undergoing surgical resection will eventually develop 1 or more metastases. Among individuals with metastatic disease, approximately 75% exhibit lung metastases, 36% have lymph node and/or soft tissue involvement, 20% have bone involvement, and 18% have liver involvement. 4 Surgical intervention remains the mainstay of primary treatment for people with RCC; however, the presence of metastatic lesions or unfortunately located primary lesions or metastases may obviate surgical intervention, leaving the person with the disease with a large tumor burden. The presence of such a burden, whether at diagnosis, after failure of induction therapy, or secondary to incomplete surgical debulking, can further complicate an already ominous situation. Since antineoplastic chemical intervention as sole therapy is almost always a futile approach (although it does little to regress tumors, it may cause neoplastic cellular apoptosis, which could be considered an immunotherapeutic adjuvant) yet causes subsequent and significant grades of toxicity in the patient receiving the treatment, as well as for the reasons presented above, immunotherapeutic intervention has become the systemic treatment of choice.
The case presented herein depicts a 61-year-old female with T2N0MX RCC, clear cell type, with sarcomatoid features, now with metastatic disease, perhaps widely spread. It is defined that the patient has bilateral pulmonary nodules consistent with a metastatic pattern, a histologically confirmed left pulmonary carcinomatous nodule, and a new, suspicious, large, right adrenal mass. I assume that the lack of presentation information regarding left perinephric lymph nodes and the adrenal gland mean that on the initial surgery, such tissues were found free of metastatic disease. Furthermore, and potentially increasing the severity of the situation at hand, the patient also claims to have progressive left scapular-based pain initiated after a trauma to that area. Of course, this could represent insult to an already metastatic lesion or perhaps a subsequently susceptible area to which the RCC metastasized as well, however, I favor the former. I suggest an immediate bone scan or positron emission tomography scan.
This patient's malignant situation appears aggressive, and I am not sure if she had received adjuvant therapy prior to her visit at the Block Center. It was stated that she was offered a milieu of treatment options but not whether she opted for any of them. I therefore assume, as is common to many patients I have worked with, that this 61-year-old female opted out of treatment until she thoroughly researched her options. Research such as this most likely led her to a facility such as the Block Center where she could receive a comprehensive approach to her disease and be treated on a very personable level. If this is the case, it is fortunate that she found an integrative cancer center yet unfortunate that she delayed her visit until after she acquired such progressive disease. I guess I am deservingly curious why the small pulmonary lesion appreciated on the January 2002 CT scan, although only 1 to 2 mm, had not been more closely followed. For instance, the patient did have 2 follow-up plain films of the chest, but such imaging is inferior to CT, and routine CT was performed only on the abdomen and pelvis. Although the initial finding on CT of the chest may indeed have been inflammatory changes, given that there seems to be absence of a left lung base lesion per CT scan in November 2002, there were still several lesions found on that particular imaging study. At that point, I would have ordered repeat CT scanning of the chest given that (1) the patient was already scheduled for a CT of the abdomen and pelvis, and additional chest imaging would not have been difficult; (2) there was a recommendation by the radiologist for follow-up CT scan; (3) there was a suspected lesion on the initial CT scan; and (4) RCC has a propensity to metastasize to the pulmonary parenchyma. The reason for this argument is that given the above "quadrad of plausibility," the metastatic process could perhaps have been recognized sooner. It is obvious that this patient does not have a slow-growing tumor. Thus, I do not understand why such a delay in treatment occurred, because the patient developed further visceral metastases during the final imaging intervalan element reflective of her prognosis, which is not favorable.
What is favorable is that her performance score is 90%, allowing for the implementation of more aggressive therapy. People with higher performance scores at the start of therapy seem to be more compliant with complicated protocols, and comprehensive therapies require attention to protocol detail and demand compliance. I would begin by doing the following on our first visit: (1) order a total-body bone scan; (2) consider a consultation with radiooncology with suspicion that the left scapular pain is secondary to a metastatic lesion (if this is true and not treated abruptly, the patient's performance status could decline rapidly, thereby confounding her ability to tolerate a comprehensive protocol and setting her up for an unnecessarily premature death); (3) place the patient on multiple natural angiogenesis inhibitors as her presentation suggests a route of hematogenous spread, and RCC is known to be an angiogenic tumor; (4) order various laboratory tests; (5) begin to devise a plan for production of an autologous, cellular immunotherapy, especially regarding autologous tissue harvest whether from existing frozen tissue or per sampling from an existing lesion; (6) discuss intravenous vitamin C therapy; (7) consider referral for possible radiofrequency ablation to the pulmonary nodules; (8) make consideration for proapoptotic therapy; (9) look into bisphosphonate therapy; (10) look into metastatectomy; (11) begin to evaluate her lifestyle via interview and questionnaire; and (12) strengthen the doctor-patient relationship since it is reasonable to believe that there was some stressful life event that took place during the imaging interval of August 2002 to November 2002 that could partially account for the aggressive metastatic spread. A strong doctor-patient relationship will enhance communication about the stressful situation.
Next, I would proceed by developing a working hypothesis regarding etiology and factors contributing to the progression of her disease (diet, nationality, cysts, smoking, toxins, hypertension, cadmium). I would then assess her lifestyle patterns and from there develop a therapeutic plan based on the 7 steps of attacking a tumor.
My approach to each patient is always to understand them as a "person with cancer" rather than a "cancer patient." By doing so, I believe I place the humanity and dignity of the person in higher regard than the cancer itself. To me, each individual that comes under my care should be treated as a person first and a patient second. This allows me to initially ignore the tumor and investigate the essence of each person in attempt to determine ways in which cancer, and then the tumor, developed in that individual. Furthermore, such an approach allows for the formation of a therapeutic doctor-patient relationship and the determination of the best way to approach treatment. Once the person and I (and perhaps family members) are familiar enough with one another, a treatment plan can be developed. I believe there are 6 mechanisms of direct antitumor therapy, and I begin my treatment plans by making a list of those 6 and subsequently placing appropriate treatment considerations under each heading, in outline form. Those 6 mechanisms are the following: Most of these mechanisms overlap or are closely associated with each other, and occasionally a medicament or medicine can be employed to serve multiple functions within the above construct, which is helpful when the goal is to produce a comprehensive protocol using a nonoverbearing number of agents. From here, I will discuss the importance of each of the mechanisms above, their significance, and their relevance to this case of RCC.
Direct cytotoxicity:
The best cytotoxic agents are the traditionally recognized chemotherapeutics. Although on literature search, it is common to find a cytotoxic effect from many different agents on select subtypes of cancer cells in vitro, this is not always true when transferred to the clinical setting. Thus, the denotation of cytotoxic is reserved for the traditional agents. Regarding RCC, chemotherapeutic agents have generally shown little efficacy 5 and are thus reserved for palliative therapy in the most metastatic of situations, usually after earlier line agents have failed to provide any therapeutic benefit. However, true sarcomatoid RCC, although rarely seen in renal neoplasms, can be relatively resistant to conventional immunotherapy protocols. 5 These types of lesions are generally treated with adriamycin-containing regimens, and recent data suggest that the addition of gemcitabine to an adrimaycin-based protocol for rapidly progressive sarcomatoid RCC may have benefits. 6 However, since the patient in this case study has a clear cell carcinoma with a sarcomatous component, meaning that the predominant histological features are of the clear cell type, I would not recommend cytotoxic agents as a sole approach to therapy.
Redifferentiation:
The reason the human body is such a wonderfully functioning marvel is due to its finiteness. Although each cell in the body retains a standard genetic code, our cooperative physiological functionality depends on the differences of our cell types. Early in embryogenesis, as a morula (16 cells in total), all the cells appear exactly similar. As development proceeds, the embryo begins to take human shape and eventually becomes a fetus and soon a developed human being with proper structures and systems. The finality of such a process relies on the terminal differentiation of our cells into functional and structural categories. When a cell becomes cancerous, it can begin to lose characteristics similar to its cohort cells-this loss occurs genealogically and can be recognized phenotypically (via histological investigation), functionally (via laboratory investigation), or genotypically (via gene chip technology). Furthermore, prognosis can depend on the degree of differentiation of the malignant cells. There is not much information available regarding the use of differentiating agents for people with RCC. There has been some initial work published looking at the potential use of vitamin D as a differentiation agent, but no conclusions have yet been made. For this reason, an agent that falls in this category would not be one that I would choose for initial treatment.
3. Novel therapeutic approaches to many types of cancer now include activation of latent or inhibition of overactive molecular pathways. Pharmaceutical companies seem to have departed somewhat from the development of next-generation cytotoxic agents in efforts to claim rank in this era of targeted therapy. As biomedical science continues to elucidate important molecular oncologic features such as receptor tyrosine kinases and apoptotic pathways, so the companies seek to develop agents that affect these targets. Alongside this, clinical laboratories have attempted to bring cellular assays, which identify crucial cellular molecular stigmata, to commercial availability. Now, armed with the ability to identify and understand molecular peculiarities of each person's individual cancer cell types, as well as useful therapeutic agents directed at such targets, it is the duty of the managing physician, whether surgeon or oncologist, to provide direction for the detection of such markers prior to the engagement of an initial therapy. Inclusion of these agents in protocols has become popularized, as evidenced by the multitude of new research using newer molecular agents in combination with more traditional drugs. More than likely, during the next several years, we will begin to see these agents in widespread use as systemic therapy, even as monother-apy, for people with cancer. This is especially true for people with metastatic disease, given the overall poor performance of chemotherapeutics, in hopes that attention paid to molecular specifics will yield enhanced response rates. Although genetic analysis of RCC tissue is available, most information gleaned from such assays is useful mainly in the initial detection of oncological lesions, for distinction from other types of neoplasms, or between RCC subtypes. More useful for therapeutic purposes seem to be the individual testing approaches that seek to identify intact antiapoptotic pathways or cell surface receptors whose presence, if activated, will induce proliferation of the cell. Several examples are as follows.
3.1. A phase II trial of a epidermal growth factor receptor (EGFR) for people with stage IV RCC. 7 According to this trial, EGFR is overexpressed in 75% to 90% of kidney neoplasms and appears to play a role in tumor initiation and progression. Twenty-one people were enrolled, and the best overall results demonstrated stabilization of disease. This is important because stabilization of disease allows synergistic agents, such as immunotherapy, a better chance at being effective.
3.2. A recent abstract 8 discussed the presence of a well-known marker, c-Kit (CD117), the prototype of molecular oncological targets. The conclusion of the study was that c-Kit is significantly overexpressed in the majority of sarcomatoid renal carcinomas, especially in the sarcomatoid compartment. Thus, c-Kit may serve as a therapeutic target for treatment of RCC, and in this case in particular since histology revealed a sarcomatous component. I think that given this information, all RCCs should be assayed for c-Kit. Since the agent, imatinib mesylate, an agent directed against c-Kit, is readily available, I consistently attempt to obtain information regarding the presence or absence of c-Kit on all solid tumors. A phase II trial using imatinib mesylate for people with RCC has so far shown efficacy in disease stabilization for people with previously progressive disease.
3.3. A recent study on females with clear cell RCC demonstrated that the presence of insulin-like growth factor-I receptor (IGF-IR) may have a prognostic implication. 9 The analysis suggested that the females with RCC exhibiting greater than 50% IGF-IR expression experienced poorer cancer-specific survival at 2 years compared with those that exhibited less than 50% expression. The following properties make the IGF-IR an interesting target in molecular oncology: (1) it suppresses apoptosis via activation of the PI3/ Akt/PKB pathway, and (2) it promotes mitogenesis via activation of the Erk/MAPK pathway. 10 Furthermore, malignant transformation as well as cancer progression have been associated with constitutive activation or increased expression of IGF-IR. Since IGF-I and its receptor play such a pivotal role in many cancers, they are attractive targets for therapy. AG 538, a new agent, and its bioisosteres (more stable isoforms) are competitive inhibitors of the IGF-IR. 10 Interruption of the signal transduced through the IGF-IR may impart decreased cell survival and proliferation. Interestingly enough, dietary choices have been implicated in high levels of IGF-I, the molecule that activates the IGF-IR. Bovine milk has been shown to contain high levels of IGF-I 11 ; adherence to a Western-type diet has also been associated with increased circulating IGF-I levels. 12 Perhaps if the IGF-IR is detected on a person's RCC, his or her physician will be aware of information such as presented here and recommend appropriate dietary strategies as treatment.
There are several other exciting molecular mechanisms whose significance has been proposed in RCC; however, the above examples suffice to drive home the point that molecular markers are important when constructing a protocol. I would suggest an analysis of any tissue available from the person in this case history, to include the markers listed above as well as other parameters, followed by the appropriate interventions.
Immunotherapy:
The cornerstone of treatment for RCC has been immunotherapy, most historically, cytokine therapy. However, since response rates for individual cytokines have peaked at an average of 20%, 13 different immunotherapeutic approaches have been and are actively being pursued. Historically, response rates to immunotherapy are interesting: true sarcomatoid RCC had demonstrated very little response 14 while clear cell RCC continues to be consistently responsive to immunotherapy. 15 It is my belief that traditional approaches to immunotherapy lack 3 main adjuvants that when used concomitantly can produce better results. These are (1) lifestyle changes, (2) mental-emotional therapy, and (3) a variety of immunoadjuvants such as intravenous vitamin C and oral supplements. Also, I believe that the proper combining of immunotherapies, whether pharmaceutical or supplemental, is crucial to produce desired results.
I recommend comprehensive immunotherapy for our patient. This section 1. will briefly present each main type of immunotherapy for RCC; 2. will not provide an extended description of the mechanisms of antitumor immunity, as this information is readily available (I have discussed such mechanisms as antigen presentation, dendritic cell pathways, and the contribution of apoptosis and antiangiogenesis therapy to this pathway elsewhere) 16 ; and 3. will provide a comprehensive, summarizing protocol that I suggest for our patient with a brief substantiation for each element, when warranted.
Cytokine therapy
4.1.1. Interleukin (IL)-2 is well known for its ability to activate native lymphocytes and natural killer cells. Because of the recognition of inactive tumor-laden lymphocytes within RCC, 17 IL-2 has been employed in attempts to activate these lymphocytes as well as peripheral lymphocytes. IL-2-based therapy is associated with (1) response rates of ≤ 20%, 14 (2) long-term survival in only a small number of patients, 18 and (3) considerable toxicity. 19 Research in the following areas attempts to overcome these problems: (1) use and comparison of low-dose versus high-dose IL-2, 20 (2) a departure from monocytokine therapy to polycytokine therapy, 21 and (3) production of IL-2 isoforms depleted of major toxicity 22, 23 (eg, 65% of patients on conventional IL-2 develop capillary-leak syndrome 19 due to increased vascular permeability and have to stop therapy). All approaches seem, at least presently, clinically pragmatic. 4.1.2. Interferon-α (INF-α) and -γ. For interferon-α, the average response rate is 15%, with a response duration of 4 to 6 months. Complete responses are rare (≤ 5%) but may be long lasting. Responses are seen predominantly in lung and lymph node metastases. 24 INF-γ appears to have no fundamental role in the treatment of metastatic RCC as the results from the sentinel study concluded that there was no difference in outcome in patients who were treated with interferon-γ-1b as compared with placebo. 24 
The intercommunication and subsequent appro-
priate behavior of the antitumor immune response relies on a complex network of interrelated cytokines. For this reason, I do not believe that monocytokine therapy as a primary approach to any type of cancer is appropriate. Based on the lack of increased response rates from monocytokine therapy, novel combinations of commercially available cytokines are being studied. There are 3 studies that I would like to briefly mention here, all which have demonstrated clinical benefit and warrant further investigation: (1) phase I trial of concurrent twice-weekly recombinant human IL-12 plus low-dose IL-2 in patients with melanoma or RCC. 25 The investigators in this study realize the importance of endogenously produced and secreted INF-γ and are using rIL-12 in attempt to upregulate this pathway. The multifunctionality of INF-γ makes the molecule a prime contributor to antitumor therapy via its effects as an immunomodulator, cell surface protein expression agonist, and contributor in the antiangiogenic cascade. (2) RCC immunotherapy with granulocyte-macrophage-colony-stimulating-factor (GM-CSF) and very low-dose subcutaneous (sc) IL-2. 26 This study has attempted to exploit the role of GM-CSF, a molecule capable of (a) conduction of the endogenous dendritic cell pathway from monocyte to maturation, (b) mobilization of CD34+ cells to the periphery, (c) improvement in IL-2 responsiveness by lymphokine-activated killer cells, and (d) overcoming tolerance to tumor-associated antigens-4 important aspects of the antitumor immune response. (3) Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2, and INF-α in patients with progressive metastatic RCC. 27 This is an appropriate combination of cytokines for the reasons stated above. The crucial aspect in successful application of polycytokine therapy is in the sequencing of the delivery schedule. The INF in this study acted, probably, as a minor immunoadjuvant and may not have been needed since INF/IL-2 combinations have shown no benefit over single-agent IL-2 studies. 28 4.2. Cellular therapies have taken advantage of the improvements in cell culture and cell-prepping techniques that have ensued over the past several years. The 3 most popular types of cellular vaccines in practice today that have been used to treat people with RCC are (1) dendritic cells (DCs), (2) lymphokineactivated killer cells (LAK), and (3) tumor-infiltrating lymphocytes (TILs) or cytotoxic T lymphocytes (CTLs). A brief description of the DC-T cell pathway is as follows: Monocytes are converted into immature dendritic cells, which are capable of phagocytosis of neoplastic cells. Once the neoplastic cells have been phagocytosed, the surface antigens are stripped off and processed by the DC. As the DC undergoes a phase of maturation, the processed antigen is shuttled to the surface of the DC for presentation to the lymphocyte. Upon encountering the matured, antigenpresenting DC, the T cell manufactures a suitable receptor, and antigen presentation takes place. The now-stimulated T cell undergoes proliferation, creating a clone of cells ready to attack the neoplastic cells bearing the presented antigen. This pathway is tightly regulated by the presence of certain surface molecules and nearby cytokines. Tumor cells are able to suppress the above response by inhibition of a number of the steps described above, hence, the immunosuppression leading to the advancement of disease and the reason why 30% of people with RCC present with metastatic disease. LAK cells differ from CTLs as they are activated killer cells that lyse tumor cells in a nonspecific fashion and do not regularly retain memory. Since tumor cells can abrupt this reaction at several checkpoints, including very late checkpoints, cellular therapy has gained popularity as a primary treatment for people with RCC. It is crucial to perform the proper qualitative immunological testing prior to choosing any immunotherapy to determine where an immunological aberrancy exists. Because of the variability in these aberrancies, some people are better candidates for polycytokine rather than a cellular therapy, based on specific testing. However, the major advantage of adoptive immunotherapy over mono-or polycytokine therapy is the ability to bypass several steps necessary for the complete endogenous antitumor response-the utility of which depends on the severity of the immunodeficiency. Overall, DC therapy has been and continues to be more well researched than LAK or CTL/TIL therapy, probably for several reasons: (1) monocytes are more easily harvested from sources than are lymphocytes, especially TILs; (2) useable DC vaccines are quicker and easier to produce than lymphocyte vaccines; (3) different techniques of DC stimulation such as fusion or antigen incorporation are more manipulable and readily available; and (4) toxicity is generally less with DC therapies. However effective any cellular therapy has been thus far, advancement in production techniques of all vaccines will continue into the future.
4.3.
Immunoadjuvants: I consider an immunoadjuvant to be any supportive measure that contributes to the overall efficacy of the primary immunotherapy. Briefly, the following adjuvants I would suggest in this case are (1) some form of mushroom preparation; (2) thymic peptides; (3) vascular endothelial growth factor (VEGF)/angiogenesis inhibitors; (4) proapoptotic agents such as selective apoptotic antineoplastic drugs (SAANDs), procedures such as radiotherapy or radiofrequency ablation, or high-quality genistein preparations; and (5) they acquire the ability to signal the immune system. Even during times of a generally suppressed immune reaction, apoptosis of cancer cells can lead to invigoration of the immune response. This is done via a promiscuous mechanism: because the antitumor immune response generally begins with phagocytic recognition of a malignant cell, if the phagocyte is unable to recognize the cell, the response generally will not proceed. By creating apoptosis in the cancer cell, the phaogocyte will be recruited toward the apoptotic signal and will proceed to engulf the apoptotic cell. Even though the phaogcyte is not initially able to recognize the cancer cell as a cancer cell, it will, nonetheless, recognize the cell surface antigens and begin to process them, then enter the pathway described above. In this way, proapoptotic mechanisms act as immunoadjuvants. For this particular patient, such proapoptotic mechanisms could be (1) radiotherapy for symptomatic or worrisome skeletal lesions and (2) 5. As stated above, this patient appears to have hematogenously disseminated disease. Angiogenesis inhibition is another way of inducing immunogenicity of tumor cells. 16 Angiogenesis plays a significant role in cancer because before tumors can grow and metastasize, the tumor first needs to be channeled with small blood vessels that allow for delivery of nutrients to the cancer cells and subsequent removal of their metabolic waste. 16 Many cancer cells can reach the systemic circulation by emancipating themselves from the parent tumor, traveling to distant, hospitable sites, and from there multiplying until another tumor is formed. Therefore, growth of new blood vessels in a solid tumor is a survival characteristic of the cancer. Inhibition of the angiogenic process can thus not only provide growth control but also would favor regression of the tumor. There are many agents in clinical practice today that have been shown to inhibit angiogenesis; however, not all are clinically applicable, and some have only limited efficacy. Angiogenesis inhibition is an important treatment modality for people with RCC because (1) RCCs are highly vascular;
(2) RCCs secrete large amounts of VEGF; (3) VEGF is involved in the growth of endothelial cells, angiogenesis, and vascular permeability; and (4) overproduction of VEGF is associated with mutations in a tumor suppressor gene, VHL, often seen in advanced clear cell RCC. 29, 30 There are 3 studies that I would like to comment on here regarding antiangiogenesis treatment for RCC.
5.1.
A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer : 31 This study evaluated the use of bevacizumab versus placebo in terms of time to progression of disease and response rates. There was a significant prolongation of the time to progression of disease in the highdose bevacizumab group as compared with the placebo group and a small difference between the time to progression of disease in the low-dose group. At the last analysis, there were no significant differences in overall survival between groups. The investigators concluded that bevacizumab could significantly prolong the time to progression of disease in patients with metastatic renal-cell cancer.
5.2. Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic RCC : 32 This agent is a selective inhibitor of 3 subtypes of the VEGF-receptor tyrosine kinases. Since this was a phase I study, the primary endpoints were to determine dose-limiting toxicity, maximum-tolerated dose, tumor response, time to progression, and overall survival. At the time this abstract was presented, there was a clinically evaluable, 19% measurable tumor response rate and a 46% rate of stable disease. Rapid disease progression occurred in only 28% of patients compared with an expected rate of 49.7% based on cytokine therapy in a similar patient population. Overall, the conclusion of the study was that PTK787/Z222584 has clinically valuable utility for people with RCC. 5.3. Phase III trial of neovastat in metastatic RCC patients refractory to immunotherapy: 33 Neovastat is a naturally occurring antiangiogenic agent for oral administration used, in this study, as a monotherapy. This marine cartilage extract is produced by AEterna, a company that also manufactures high-quality nutritional supplements. The primary endpoint is median survival time. The trial has enrolled 302 patients. Full data are not yet available; however, the phase I and II trials demonstrated positive results. 5.4. Some other available angiogenesis inhibitors that I have used include GCP (mentioned above), melatonin, artemisinin, the botanical Convolvulus arvensis, and various cyclooxygenase-2 inhibitors. Overall, I would recommend a combination of multiple angiogenesis inhibitors as initial therapy combined with the other agents already mentioned above.
6. The last in my list of antitumor mechanisms is mental-emotional therapy. I have theorized on this in a more ethereal sense rather than researched this element in terms of collecting relevant references that demonstrate effect on tumors from such techniques. Although such data are available, I believe it would be too contrived to list studies that prove that when people with cancer face and deal with their personal issues, their tumors are affected in a way positive for the person. I say this because this type of treatment is truly an individualized therapy. I have made inquiry to almost every person I treat with cancer, whether there was some type of significant life event that occurred either in the 18 or so months prior to their initial diagnosis or within their time-to-progression interval should they have developed metastatic disease. I have received positive answers in more than 80% of the people who have responded to my question. Although I do not treat people using mental-emotional techniques, I quickly offer referrals to practitioners who can help in this area. It is my philosophical belief that in almost every case of cancer, there is some contribution by the mental-emotional component acting as a growth factor for the disease, albeit differently in each case. This reflects the notion that a tumor is merely a symptom of cancer and that the word cancer describes the environment of a person's body that allowed for neoplastic changes in a certain cell type. While all of the mechanisms listed above are suitable antitumor therapies, not all are truly anticancer therapies. As stated before, tumors need growth factors to grow or progress. Withdrawal of growth factors in the physical sense has resulted in regression of tumors. It seems reasonable to me that similar effects would occur if the mental-emotional growth factor were withdrawn. In this sense, when dealing with tender but crucial emotional issues, one would actually be bridging the gap between mind and body.
What I have presented here is my interpretation of this person's case and the basis for the treatment plan that I would engage at the outset. I always attempt to recognize relevant data from the literature and combine that with knowledge gained from my clinical experience. Data achieved from well-controlled trials do not always translate into absolute clinical efficacy, and at times, agents that have not shown significance in clinical trials will work for the patient sitting in front of you. Treatment of people with cancer in the metastatic setting allows for leniency and affords the luxury to depart from trial data in that the endpoint is always survival time. I have found that a protocol developed from both science and experience that is malleable and well understood by the patient provides the best outcome.
